← 返回

岩藻多糖通过激活 STAT3 信号通路增强 CAR-T 细胞抗非霍奇金淋巴瘤的疗效

英文原题:Fucoidan potentiates anti-tumor efficacy of CAR-T cells against non-Hodgkin lymphoma by activation of STAT3 pathway.

查看英文原题

Fucoidan potentiates anti-tumor efficacy of CAR-T cells against non-Hodgkin lymphoma by activation of STAT3 pathway.

PubMed 2025/12/13(内容时间) J Transl Med Q1 · IF 9.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

这些发现阐明了 FO 在增强 CAR-T 细胞功能中的支持作用,表明 FO 作为免疫调节补充剂具有临床潜力,可增强 CAR-T 疗法对 NHL 的疗效。

研究思路结论见上方概要

尽管CAR-T 细胞疗法取得了进展,但仍存在重大挑战,包括进行性T细胞耗竭和体内持久性差。当前增强CAR-T 功能的策略——如细胞因子共表达——往往导致严重的不良反应,最显著的是细胞因子释放综合征(CRS)。因此,迫切需要开发更安全、更可持续的方法,特别是通过营养干预,来提高CAR-T 疗法的抗肿瘤疗效。岩藻多糖(FO)是一种来源于海洋植物的生物活性多糖,已显示出免疫调节特性以及与常规化疗联合的协同潜力。然而,其在细胞免疫治疗(包括CAR-T 疗法)中的作用尚未被探索。本研究旨在阐明FO在非霍奇金淋巴瘤(NHL)CAR-T 治疗中的功能,并为其在细胞免疫治疗领域的临床转化提供基础依据。

本研究采用体外和体内实验相结合的方法,探讨FO在CAR-T 疗法中的作用。通过含有CAR-CD19结构的慢病毒构建抗CD19 CAR-T 细胞。对于CAR-T 细胞的表型分析,通过细胞标志物染色并用流式细胞术鉴定不同的细胞群体,如记忆型和耗竭型CAR-T 细胞。将来自不同处理组的CAR-T 细胞与靶细胞以不同的E:T比例共培养,以检测CAR-T 细胞的细胞毒性和细胞因子释放。我们还在荷瘤小鼠模型中评估了FO对CAR-T 细胞功能的支持作用。同时研究了激活信号通路的潜在机制,并通过抑制剂进行了验证。

在本研究中,我们系统探讨了FO在抗CD19 CAR-T 细胞介导的NHL治疗中的作用。具体而言,FO增强了CAR-T 细胞的记忆维持和抗耗竭能力。FO不仅提高了CAR-T 细胞的抗氧化能力和增殖能力,还阻止了活化CAR-T 细胞的凋亡,共同促进了体外实验和异种移植模型中抗肿瘤疗效的提高和持久性。我们的机制研究还揭示,FO通过增强STAT3信号通路的激活,作为CAR-T 细胞功能的增强剂。

展开英文摘要原文

Despite advances in chimeric antigen receptor T-cell (CAR-T) therapy, significant challenges remain, including progressive T-cell exhaustion and poor in vivo persistence. Current strategies to enhance CAR-T function-such as cytokine co-expression-often lead to severe adverse effects, most notably cytokine release syndrome (CRS). Therefore, there is a pressing need to develop safer and more sustainable approaches, particularly through nutritional interventions, to improve the antitumor efficacy of CAR-T therapy. Fucoidan (FO), a bioactive polysaccharide derived from marine plants, has demonstrated immunomodulatory properties and synergistic potential in combination with conventional chemotherapy. However, its role in cellular immunotherapy, including CAR-T therapy, has not yet been explored. This study aims to elucidate the function of FO in CAR-T therapy for non-Hodgkin lymphoma (NHL) and to provide a foundational basis for its clinical translation in the field of cellular immunotherapy.

The current study used a combination of in vitro and in vivo assays to explore the role of FO in CAR T therapy. The anti-CD19 CAR-T cells were constructed by lentivirus containing CAR-CD19 structure. For phenotype analysis of CAR T cells, different cell populations, such as memory and exhausted CAR T cells, were stained by cell marker and identified by flow cytometry. CAR-T cells from different treatment groups were co-cultured with target cells with different E: T ratio to detect the cytotoxicity and cytokine release of CAR-T cells. We also evaluate FO's supportive role for function of CAR-T cells in the tumor-bearing mouse models. The underlying mechanism of activated signaling pathway were also investigated and confirmed by the inhibitor.

In this study, we systematically investigated the role of FO in anti-CD19 CAR-T cell-mediated treatment of NHL. Specifically, CAR-T cells' memory maintenance and exhaustion resistance were enhanced by FO. FO not only improved CAR-T cell's antioxidant capacity and proliferation, but also prevented apoptosis of activated CAR-T cells, collectively contributing to the improved and sustained anti-tumor efficacy in both in vitro assays and xenograft models. Our mechanistic studies also revealed FO served as a potentiator for CAR-T cells' function through enhancing the activation of STAT3 signaling pathway.

These findings elucidate the supportive role of FO in enhancing CAR-T cell function, which indicates FO's clinical potential as immunomodulatory supplement to potentiate CAR-T therapy against NHL.

论文信息

作者
Kang Q、Zhang L、Wu X、Shi X
第一作者单位
Medical Research Center, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518033, China.China
通讯作者单位
Department of Hematology and Oncology, Shenzhen University General Hospital, Shenzhen, 518055, China. sxr0323@szu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Journal of translational medicine2025 Dec 13
原文标识
PubMed 41390428 · DOI 10.1186/s12967-025-07548-2